JP2005516017A - 向上した薬物動態特性を示す医薬コンジュゲート - Google Patents
向上した薬物動態特性を示す医薬コンジュゲート Download PDFInfo
- Publication number
- JP2005516017A JP2005516017A JP2003552332A JP2003552332A JP2005516017A JP 2005516017 A JP2005516017 A JP 2005516017A JP 2003552332 A JP2003552332 A JP 2003552332A JP 2003552332 A JP2003552332 A JP 2003552332A JP 2005516017 A JP2005516017 A JP 2005516017A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- component
- pharmaceutical conjugate
- linker
- memantine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
で表される。
本発明の他の利点および側面は、本願請求項および以下の詳細な説明から明らかである。
α2アドレナリン作動剤として機能する上記化合物の類似体も、特に本発明によって包含されるものとする。
好ましくは、α2アドレナリン作動剤、例えば上述のものは、α2Aアドレナリン受容体、α2Bアドレナリン受容体およびα2Dアドレナリン受容体の1または複数の活性化に有効である。
で表される。
リンカーの例を以下に挙げるが、これらに限るわけではない:
本発明のいくつかの側面を、非限定的な以下の実施例で説明する。
局所眼科用1−アミノ−3,5−ジメチルアダマンタン塩酸塩(メマンチン)点眼剤の全般的動態をオートラジオグラフィーによって評価した。簡単に述べると、アルビノウサギおよび有色ウサギに、0.74%等張性メマンチン水溶液(pH7.4)を、局所点眼によって投与した。投与に続いて、投与の0.25、0.5、1、2および24時間後に、眼のオートラジオグラフィーデータを得た。オートラジオグラフィーデータは、局所投与後のメマンチンが後部強膜、脈絡膜および/または網膜中に存在することを、はっきりと示した。さらに、このデータから、滞留時間の定性的評価を行うことができた。眼球後部におけるメマンチンの半減期は、アルビノウサギでも有色ウサギでも、比較的長いようだった。有色組織におけるオートラジオグラフィーの強度から、メマンチンは眼のメラニンに結合していることがわかった。
本発明をさまざまな具体的実施例および実施形態に関して説明したが、本発明はそれらに限定されるわけではなく、本願請求項の範囲でさまざまな形に実施することができると理解すべきである。
Claims (23)
- 処置成分と効力向上成分とが共有結合によって直接連結されている請求項1に記載の医薬コンジュゲート。
- 処置成分と効力向上成分とがリンカーによって連結されている請求項1に記載の医薬コンジュゲート。
- R1およびR2がHであり、R3がリンカーである請求項1に記載の医薬コンジュゲート。
- 効力向上成分がメマンチンである請求項1に記載の医薬コンジュゲート。
- 処置成分が、NMDA拮抗剤、抗菌剤、抗ヒスタミン剤、鬱血除去剤、抗炎症剤、抗寄生虫剤、縮瞳剤、抗コリン剤、アドレナリン作動剤、抗ウイルス剤、局所麻酔剤、抗真菌剤、殺アメーバ剤、殺トリコモナス剤、鎮痛剤、散瞳剤、抗緑内障剤、炭酸脱水酵素阻害剤、眼科診断剤、手術中に補助剤として使用される眼科剤、キレート剤、抗新生物剤、抗高血圧剤、筋弛緩剤、診断剤、チロシンキナーゼ阻害剤および神経保護剤からなる群より選択される請求項1に記載の医薬コンジュゲート。
- 処置成分が、キノキサリン、(2-イミダゾリン-2-イルアミノ)キノキサリン、5-ブロモ-6-(2-イミダゾリン-2-イルアミノ)キノキサリン、それらの誘導体およびそれらの混合物からなる群より選択される請求項1に記載の医薬コンジュゲート。
- 処置成分およびメマンチンを含んでなり、リンカーが処置成分およびメマンチンを連結する請求項1に記載の医薬コンジュゲート。
- チモロールおよびメマンチンを含んでなり、リンカーがチモロールおよびメマンチンを連結する請求項1に記載の医薬コンジュゲート。
- 5-ブロモ-6-(2-イミダゾリン-2-イルアミノ)キノキサリンおよびメマンチンを含んでなり、リンカーが5-ブロモ-6-(2-イミダゾリン-2-イルアミノ)キノキサリンおよびメマンチンを連結する請求項1に記載の医薬コンジュゲート。
- 処置成分および効力向上成分が生理的条件下に解離する請求項1に記載の医薬コンジュゲート。
- 局所投与用である請求項1に記載の医薬コンジュゲート。
- 効力向上成分に連結されていない同じ処置成分を含んでなる化合物よりも、水溶性、分配係数および/またはメラニン親和性が高い請求項1に記載の医薬コンジュゲート。
- 塩である請求項1に記載の医薬コンジュゲート。
- R1およびR2がHであり、R3がリンカーである請求項17に記載の方法。
- 効力向上成分がメマンチンである請求項17に記載の方法。
- 処置成分が、NMDA拮抗剤、抗菌剤、抗ヒスタミン剤、鬱血除去剤、抗炎症剤、抗寄生虫剤、縮瞳剤、抗コリン剤、アドレナリン作動剤、抗ウイルス剤、局所麻酔剤、抗真菌剤、殺アメーバ剤、殺トリコモナス剤、鎮痛剤、散瞳剤、抗緑内障剤、炭酸脱水酵素阻害剤、眼科診断剤、手術中に補助剤として使用される眼科剤、キレート剤、抗新生物剤、抗高血圧剤、筋弛緩剤、診断剤、チロシンキナーゼ阻害剤および神経保護剤からなる群より選択される請求項17に記載の方法。
- 投与経路が局所である請求項17に記載の方法。
- 投与経路が経口、直腸、舌下、鼻および/または静脈内である請求項17に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/016,850 US20030114460A1 (en) | 2001-12-14 | 2001-12-14 | Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
PCT/US2002/040153 WO2003051400A1 (en) | 2001-12-14 | 2002-12-13 | Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005516017A true JP2005516017A (ja) | 2005-06-02 |
Family
ID=21779317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003552332A Pending JP2005516017A (ja) | 2001-12-14 | 2002-12-13 | 向上した薬物動態特性を示す医薬コンジュゲート |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030114460A1 (ja) |
EP (1) | EP1455837A1 (ja) |
JP (1) | JP2005516017A (ja) |
AU (1) | AU2002360613B2 (ja) |
CA (1) | CA2471589A1 (ja) |
WO (1) | WO2003051400A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
CN1753683B (zh) * | 2002-12-20 | 2010-05-26 | 视可舒研究公司 | 预防和治疗不良眼部病症的眼用制剂 |
US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
US20060166879A1 (en) * | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
US20050277698A1 (en) * | 2004-01-05 | 2005-12-15 | Hughes Patrick M | Memantine delivery to the back of the eye |
US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
WO2006127217A2 (en) * | 2005-05-25 | 2006-11-30 | Eli Lilly And Company | Cyclopropanecarboxylate esters of acyclovir |
WO2007011843A2 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Prevention and treatment of ophthalmic complications of diabetes |
US20070154523A1 (en) * | 2005-12-30 | 2007-07-05 | Rick Lewis | Controlled pupil dilation for diagnostic and treatment of visual anomalies |
WO2007117544A2 (en) * | 2006-04-07 | 2007-10-18 | Ssv Therapeutics, Inc. | Carnitine conjugates of adamantanamines and neramexane derivatives as duel prodrugs for various uses |
WO2008018877A1 (en) * | 2006-08-11 | 2008-02-14 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs, methods of production and uses thereof |
US7727978B2 (en) * | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8119658B2 (en) * | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
CN102525899B (zh) * | 2012-01-17 | 2013-04-17 | 山东罗欣药业股份有限公司 | 一种奥拉西坦组合物注射液及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6441047B2 (en) * | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
DE19948651B4 (de) * | 1999-09-29 | 2006-10-05 | Schering Ag | Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung |
BR0112461A (pt) * | 2000-07-14 | 2003-07-22 | Allergan Inc | Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada |
-
2001
- 2001-12-14 US US10/016,850 patent/US20030114460A1/en not_active Abandoned
-
2002
- 2002-12-13 JP JP2003552332A patent/JP2005516017A/ja active Pending
- 2002-12-13 WO PCT/US2002/040153 patent/WO2003051400A1/en active Application Filing
- 2002-12-13 AU AU2002360613A patent/AU2002360613B2/en not_active Ceased
- 2002-12-13 CA CA002471589A patent/CA2471589A1/en not_active Abandoned
- 2002-12-13 EP EP02795884A patent/EP1455837A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1455837A1 (en) | 2004-09-15 |
WO2003051400A1 (en) | 2003-06-26 |
AU2002360613A1 (en) | 2003-06-30 |
CA2471589A1 (en) | 2003-06-26 |
US20030114460A1 (en) | 2003-06-19 |
AU2002360613B2 (en) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9907801B1 (en) | Combination of brimonidine and timolol for topical ophthalmic use | |
ES2332049T3 (es) | Composiciones para administracion de sustancias terapeuticas en los ojos y procedimientos para prepararlas y usarlas. | |
US7491383B2 (en) | Compositions having enhanced pharmacokinetic characteristics | |
JP2005516017A (ja) | 向上した薬物動態特性を示す医薬コンジュゲート | |
US7642258B2 (en) | Combination of brimonidine and timolol for topical ophthalmic use | |
JP2006508120A5 (ja) | ||
KR20130092957A (ko) | 안과용 처방용 보존제 조성물의 조합 | |
WO2002040028A1 (fr) | Gouttes pour les yeux en gel antibacterien | |
AU2002256471B2 (en) | Compositions having enhanced pharmacokinetic characteristics | |
AU2007254671B2 (en) | Combination of brimonidine and timolol for topical ophthalmic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051201 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080911 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090819 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090826 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090916 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091019 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091222 |